Glucotrack, Inc. (GCTK) Form S-1 — Sep 17, 2026
Glucotrack filed an S-1 registering 43,447,017 resale shares for selling stockholders, equal to roughly 5,442% of its 798,390 shares outstanding. The registration covers shares underlying a $50 million equity line with White Lion Capital, $7.95 million of Bridge convertible notes, a $2 million Interim PIPE, and an $11.6 million September PIPE, with shares outstanding rising to 44,245,407 if fully issued. Existing holders face extreme dilution; the stock trades at $2.45 versus a $5.9868 minimum price threshold and $7.50 warrant strike.
Key figures
- Cash Position
- $3.9 million (as of March 31, 2026)
- Gross Proceeds
- up to $50.0 million potential under ELOC Purchase Agreement; no proceeds from Selling Stockholder resales
- Offering Price
- no fixed price; ELOC purchases at lowest traded price (Rapid) or 97% of 3-day lowest VWAP (VWAP); last reported sale price $2.45 (September 14, 2026)
- Shares Offered
- 43447017
- Merger date
- July 14, 2026
- Interest rate
- 8% per annum
- Minimum price
- $5.9868
- Note maturity
- nine (9) months from issuance
- True up amount
- $1,000,000 if Commitment Fee Price below Minimum Price
- Eloc period years
- 3
- Eloc purchase price
- lowest traded price (Rapid) or 97% of 3-day lowest VWAP (VWAP)
- Reverse split ratio
- 1-for-15 (effective August 28, 2026)
- September notes cash
- $4,500,000
- Commitment fee shares
- 167035
- Equity rule threshold
- $2,500,000
- Conversion price floor
- 20% of Nasdaq Minimum Price
- September exchange cap
- 19.99% of outstanding shares
- Registered shares total
- 43447017
- Warrant coverage bridge
- 125%
- Commitment warrant value
- $10,000,000
- September notes exchanged
- $4,545,014.69
- September notes principal
- $11,596,172.68
- September warrants shares
- 4831739
- Registered shares under eloc
- 8351708
- Shares outstanding surge pct
- approximately 5,442%
- Notes original issue discount
- 22%
- Subsidiary contribution total
- $7,000,000 (of which $1,025,000 funded as of September 14, 2026)
- Accumulated deficit march 2026
- $156.2 million
- Bridge warrants exercise price
- $35,000,000 divided by total outstanding shares at exercise
- Financing gross proceeds total
- approximately $14.45 million ($7.95M Bridge + $2.0M Interim PIPE + $4.5M September cash)
- Pre offering shares outstanding
- 798390
- September conversion cap shares
- 159598
- Post offering shares outstanding
- 44245407
- Accumulated deficit december 2025
- $151.8 million
- September warrants exercise price
- $7.50 per share, 5-year term
- Bridge notes face amount outstanding
- approximately $7,111,538
- Registered shares pct of outstanding
- 5,442%
- Aggregate purchase price september notes
- $9,045,014.69
- Bridge notes face outstanding after september exchange
- approximately $1,336,914.24
AI analysis
Red flags12 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.